CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil
October 25, 2021 06:00 ET
|
CytoDyn Inc.
Based on previous strong sub-population analysis in CD12 trial, CytoDyn intends to file for an EUA when interim analysis of 127 patients is completed VANCOUVER, Washington, Oct. 25, 2021 (GLOBE...
CytoDyn to Hold Webcast and Live Q/A on October 26
October 21, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A
October 07, 2021 14:27 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)
October 07, 2021 06:02 ET
|
CytoDyn Inc.
Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint...
CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV
October 07, 2021 06:01 ET
|
CytoDyn Inc.
New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with...
CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research
October 07, 2021 06:00 ET
|
CytoDyn Inc.
All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan VANCOUVER,...
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A
September 13, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms
September 09, 2021 20:30 ET
|
CytoDyn Inc.
An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:...
CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials
September 02, 2021 18:40 ET
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs
August 26, 2021 17:02 ET
|
CytoDyn Inc.
Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led...